Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Meitav Investment House Ltd.

Meitav Investment House Ltd. cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 37.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 39,116 shares of the biopharmaceutical company's stock after selling 23,884 shares during the period. Meitav Investment House Ltd.'s holdings in Halozyme Therapeutics were worth $1,870,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. CWM LLC grew its holdings in Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company's stock valued at $88,000 after purchasing an additional 668 shares during the last quarter. Creative Planning grew its holdings in Halozyme Therapeutics by 25.6% during the 3rd quarter. Creative Planning now owns 46,834 shares of the biopharmaceutical company's stock valued at $2,681,000 after purchasing an additional 9,543 shares during the last quarter. Raymond James & Associates grew its holdings in Halozyme Therapeutics by 87.1% during the 3rd quarter. Raymond James & Associates now owns 273,591 shares of the biopharmaceutical company's stock valued at $15,660,000 after purchasing an additional 127,330 shares during the last quarter. FSC Wealth Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter valued at about $65,000. Finally, Private Advisor Group LLC grew its holdings in Halozyme Therapeutics by 6.2% during the 3rd quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company's stock valued at $1,383,000 after purchasing an additional 1,410 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Up 0.5 %

NASDAQ:HALO traded up $0.31 during midday trading on Friday, reaching $57.75. 1,299,523 shares of the stock traded hands, compared to its average volume of 1,313,186. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53. The business has a 50-day moving average of $53.46 and a two-hundred day moving average of $54.62. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a market capitalization of $7.11 billion, a PE ratio of 16.84, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.72 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on HALO shares. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a research report on Wednesday. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Benchmark reaffirmed a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday. Finally, JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.